TEC-006OL

Indication

Moderate to severe inadequately controlled cancer-related pain.

Stage
Phase III

Location
Canada

Description
The objective of the trial is to evaluate the long-term efficacy and safety of repeated cycles of Tectin™ in patients with moderate to severe inadequately controlled cancer-related pain.  The trial is a multicentre, open-label trial enrolling only those patients who participated n the TEC-006 trial, both those who received Tectin™ and those who received placebo.  Patients will be administered Tectin™ subcutaneously for a treatment period of four days.  Efficacy and safety assessments will be conducted over a period of fifteen days or until pain returns.  Multiple cycles of Tectin™ will be given as long as patients experience pain relief. 

The primary endpoint for the trial is a composite of pain outcome and quality of life measurements.  The secondary endpoints include the duration of analgesia following repeated cycles of Tectin™.

Status
This trial is currently enrolling patients.

Further Information
This trial is only open to patients enrolled in the TEC-006 trial.

For further details, please visit ClinicalTrials.gov.